Neuropsychiatric Disturbances in Mild Cognitive Impairment (MCI): A Systematic Review of Population-Based Studies

Cristiano A Köhler, Thaís F Magalhaes, Joao M M P Oliveira

  • 1Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Rua Prof. Costa Mendes, 1608, 4º andar, 60430-040, Fortaleza, CE, Brazil.

Insights

Behavioral and psychological symptoms of dementia (BPSDs) are common in mild cognitive impairment (MCI). This systematic review found depression, sleep disturbances, and apathy are prevalent in community-dwelling individuals with MCI.

Area of Science:

  • Neurology
  • Gerontology
  • Psychiatry

Background:

  • Mild cognitive impairment (MCI) is a precursor to dementia, often accompanied by behavioral and psychological symptoms of dementia (BPSDs).
  • Neuropsychiatric manifestations in MCI may predict dementia conversion.
  • No recent systematic review has comprehensively assessed BPSD prevalence in general population samples of MCI.

Purpose of the Study:

  • To conduct a systematic review on the prevalence of any or specific BPSDs in individuals with MCI from general population samples.
  • To compare BPSD prevalence in MCI with cognitively intact and demented individuals.

Main Methods:

  • Systematic review of studies published from January 1, 1990, to January 3, 2015.
  • Searched PubMed/MEDLINE, EMBASE, and PsycInfo databases for general population studies estimating BPSD prevalence in MCI.
  • Included 21 studies, assessing methodological quality using a modified New Castle-Ottawa Scale.

Main Results:

  • Depression (median 29.8%), sleep disturbances (median 18.3%), and apathy (median 15.2%) were the most frequent BPSDs in MCI.
  • The overall prevalence of any BPSD in MCI ranged from 12.8% to 66.0%.
  • No consistent patterns in BPSD prevalence were observed across different MCI subtypes.

Conclusions:

  • BPSDs are highly prevalent in community-dwelling individuals with mild cognitive impairment.
  • Further research is needed to establish consistent socio-demographic and clinical correlates for BPSDs in the MCI population.
  • Varied diagnostic criteria and assessment tools for MCI and BPSDs across studies limit direct comparisons.

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
809
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
312
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
663